Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report - Takeaways - MDSpire

Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report

  • By

  • Hui Huang

  • Haiguo Yu

  • Zhidan Fan

  • Yihong Guo

  • Huihui Ma

  • Na Huang

  • Le Ma

  • May 7, 2026

  • 0 min

Share

  • 1

    Calcinosis cutis is a challenging complication of dermatomyositis, particularly in patients with anti-NXP2 autoantibodies.

  • 2

    In a study of nine patients, TNF-α antagonists led to significant clinical improvement and reduced glucocorticoid use.

  • 3

    Radiographic improvement of calcinosis was observed in 2 of 3 anti-NXP2-positive patients after 12–20 months of TNF-α inhibition.

  • 4

    Calcinosis was absent at baseline in all anti-NXP2-negative individuals, limiting the evaluation of treatment effects in this group.

  • 5

    The findings suggest that antibody status may influence calcinosis responsiveness to TNF-α inhibition, warranting further research.

Original Source(s)

Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report

  • by Hui Huang, Haiguo Yu, Zhidan Fan, Yihong Guo, Huihui Ma, Na Huang, Le Ma

  • May 7, 2026

Related Content

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min
NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses